US20100197962A1 - Use of Neboglamine in the Treatment of Toxicodependency - Google Patents

Abstract

Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.

Description

• The present invention relates to a novel use of (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249-neboglamine) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for use in the treatment of toxicodependency induced by drugs such as Central Nervous System (CNS) sedatives such as opiates, benzodiazepines, barbiturates, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.
• The term “toxicodependency”, whether physical or psychological, means the continued and totally implicit use of a drug. Such a use involves the risk of physical damage and the need to stop or limit the consumption of the substance, whether or not the drug taker is in agreement.
• The term “psychological dependency” means an irresistible impulse (compulsion) to continue self-administering the drug in order to find pleasure. For certain drugs, the psychological dependency is the most important factor in their compulsive use.
• The term “physical dependency” means a state of habituation to the drug accompanied by tolerance and that is manifested by abstinence syndromes.
• Tolerance is the need to increase the dose of the drug in order to obtain the same effects as were initially obtained with lower doses; the abstinence syndrome is characterized by painful physical sensations that are manifested when the taking of the drug is stopped.
• The substances commonly used by drug takers all induce psychological dependency, while others (the majority) also induce physical dependency.
• The following groups may be distinguished: CNS sedatives such as opiates, benzodiazepines, barbiturates and alcohol, which also all induce physical dependency and tolerance; CNS stimulants, for instance amphetamine and cocaine which induce physical dependency to a minor extent, if at all; hallucinogens such as LSD, mescalin, cannabis (marijuana) and fencyclidine.
• On the basis of published preclinical data, the compound neboglamine (CR 2249) has been shown to have significant modulatory properties on the glycine site (strychnine-insensitive) coupled to the NMDA receptor complex [Lanza et al., Neuropharmacology 36, 1057-64 (1997)], and also advantageous properties of promoting memory and learning in various animal models [Garofalo et al. J. Pharm. Pharmacol. 48, 1290-97 (1996)]. The facilitatory activity exerted by neboglamine on the NMDA receptor complex should be of therapeutic use in conditions of glutamatergic hypo functionality.
• It has been suggested that the NMDA receptor complex may be involved in a variety of functional responses to cocaine, for instance locomotor activity, dependency (continued reinforcement of self-administration), tolerance and toxicity (Rockhold R. W., Progress in Drug Research 50: 155-92, 1998).
• It has also recently been demonstrated that glycine is capable of inhibiting the locomotor hyperactivity, tolerance and dependency induced by morphine in mice (K. W. Shin et al., Arch. Pharm. Res. 26: 1074-1078, 2003).
• Thus, neboglamine was evaluated in animal experimental models that may be considered as predictive for the evaluation of toxicodependency induced by various drugs such as cocaine, morphine and benzodiazepines, which are widely representative of the syndromes caused by toxicodependency.
• In the first model used, the inhibitory effect of neboglamine and glycine on the hypermotility induced by cocaine and morphine in rats was evaluated.
• The motor activity was measured with a video camera and recorded using the Videotrack 512 system as described by Garofalo (J. Pharm. Pharmacol. 48: 1290-1297, 1996).
• Physiological saline, neboglamine (30 mg/kg) or glycine (300 mg/kg) were administered via the i.p. route 30 minutes before physiological saline, morphine (10 mg/kg s.c.) or cocaine (20 mg/kg s.c.).
• The locomotor activity was recorded for 15 minutes and the total distance covered (in cm) by the animal was recorded by the computer connected to the video camera. The results thus obtained are collated in Table 1.

• TABLE 1
  Inhibitory activity of neboglamine and glycine on the
  locomotor hyperactivity induced by cocaine and morphine

  		Total	% increase vs.
  	Dose	distance	physiological	% inhibition vs.
  Treatment	(mg/kg)	(cm)	saline	the drug (D)
  Physiological	F + F	3300	—	—
  saline (F)
  Neboglamine	30 + F	3150	(−)4.5	—
  (N)
  Glycine (G)	300 + F	2900	(−)12.1	—
  Cocaine (C)	F + 20	5800	75.7	—
  Morphine (M)	F + 10	5300	60.6	—
  N + C	30 + 20	3600	9.1	88.0(1)
  N + M	30 + 10	3750	13.6	77.5(1)
  G + M	300 + 10	4250	28.8	52.5(2)

  ${}^{\left(1\right)}\mathrm{The}\%\mathrm{inhibition}\mathrm{is}\mathrm{calculated}\mathrm{by}\mathrm{the}\mathrm{formula}\text{:}\frac{\left[D-\left(D+N\right)\right]}{D-F}\times 100$

  ${}^{\left(2\right)}\mathrm{The}\%\mathrm{inhibition}\mathrm{is}\mathrm{calculated}\mathrm{by}\mathrm{the}\mathrm{formula}\text{:}\frac{\left[D-\left(D+G\right)\right]}{D-F}\times 100$

• From the data given in Table 1, it may be seen that both cocaine and morphine show a marked increase in locomotor activity (75.7% and 60.6%, respectively), whereas neboglamine and glycine do not significantly alter the spontaneous motility of the animal.
• The motor activity accelerated by both the drugs cocaine and morphine is almost completely antagonized by doses of 30 mg/kg i.p. of neboglamine (88% and 77.5%, respectively). Glycine also inhibits the morphine-induced hyperkinetic activity, but with a smaller effect (52.5%) and at doses 10 times higher (300 mg/kg as opposed to 30 mg/kg of neboglamine).
• In a second experiment, the capacity of neboglamine to inhibit the increased sensitivity (inverse tolerance) induced in rats was evaluated by chronic treatment with morphine.
• Neboglamine (30 mg/kg) or physiological saline were administered via the i.p. route 30 minutes before morphine (10 mg/kg s.c.) for 6 days. On the seventh day, the test was performed, as described in the preceding experiment, in comparison with a group of animals treated with the same dose of morphine given acutely only on the 7th day (final day of the, experiment). The results thus obtained are collated in Table 2.

• TABLE 2
  Inhibitory activity of neboglamine on the inverse tolerance
  induced by chronic treatment with morphine in rats

  			% increase	% inhibition of
  		Total	vs.	the
  	Dose	distance	physiological	hypersensitivity
  Treatment	(mg/kg)	(cm)	saline	of morphine
  Physiological	—	2800	—	—
  saline (F)
  Morphine	10 (s.c)	5050	80.3	—
  Chronic morphine	10 (s.c.) ×	6400	128.6	—
  (MC)	7 days
  CM + neboglamine	10 (s.c.) +	3850	37.5	70.8(1)
  (N)	30
  	(N i.p.) ×
  	7 days

  ${}^{\left(1\right)}\mathrm{The}\%\mathrm{inhibition}\mathrm{is}\mathrm{calculated}\mathrm{by}\mathrm{the}\mathrm{formula}\text{:}\frac{\left[\mathrm{MC}-\left(\mathrm{MC}+N\right)\right]}{\mathrm{MC}-F}\times 100$

• Chronic treatment with morphine induces an increase in the motor activity of the rat, compared with the acute effect of the drug, by about 50% (128.6% as opposed to 80.3%). Chronic pre-treatment with neboglamine (30 mg/kg i.p for 7 days) succeeds in almost completely antagonizing (70.8%) the development of the inverse tolerance induced by the chronic treatment with morphine.
• In a third experiment, we wished to study the effect of neboglamine both on the tolerance induced by a prolonged treatment with a benzodiazepine (diazepam) and on the abstinence crisis (“withdrawal”) produced by stopping the chronic treatment with diazepam.
• The experiment was performed in an elevated zero maze in accordance with the procedure described by Shepard et al. (Psychopharmacology 116: 56-64, 1994) with minor changes.
• The rat, placed in one of the closed quadrants, had free access to all 4 of the quadrants (2 open and 2 closed) for a period of 5 minutes. A compound with anxiolytic activity produces a percentage increase in the time spent in the free quadrants.
• In the acute studies, the compounds were administered via the s.c. route 30 minutes before the experiment, whereas in the tolerance and “withdrawal” experiments, they were administered via the s.c. route twice a day for 7 days and then retested 40 hours after the end of the chronic treatment. The results thus obtained are collated in Table 3.

• TABLE 3
  Effects of neboglamine on the tolerance and abstinence crisis
  induced by chronic treatment with diazepam in rats

  		Time (seconds)	% effect vs.
  	Dose	spent in the	controls
  Treatment	(mg/kg) s.c.	open quadrants	(saline)

  Physiological saline	—	40	100.0
  Acute diazepam (D)	5	105	262.5
  Chronic diazepam (D-C)	5 × 2 (×7 days) + 5 (D)	58	145.0
  Acute neboglamine (N)	30	51	127.0
  Physiological (D-W)	—	15	37.5
  Neboglamine+ (D-C)	30 × 2 (×7 days) + 30 + 5 (D)	77	192.5
  Neboglamine (D-W)	—	44	110.0
  Note:
  Physiological (D-W) is the group treated with diazepam for 7 days and retested 40 hours later with physiological saline.
  Neboglamine (D-W) is the group treated with diazepam and neboglamine for 7 days and retested 40 hours later with physiological saline

• 5 mg/kg s.c. of diazepam produce a significant anxiolytic effect (i.e. an increase in residence in the open quadrants): 262.5% compared with the control group.
• The treatment continued for 7 days induces tolerance with a decrease in the anxiolytic effect from 262.5% to 145% compared with the control group. Neboglamine displays non-significant anxiolytic activity (127% compared with the controls). However, its co-administration with diazepam does not reduce tolerance (192.5% effect compared with the control). In addition, the co-administration of neboglamine was shown to inhibit the abstinence crisis induced by stoppage of the chronic treatment with diazepam [110% of effect for the group N-(D-W) as opposed to 37.5% of effect for the group (D-W)].
• In accordance with that presented above, a subject of the invention is pharmaceutical compositions comprising as active principle neboglamine or the racemic mixture thereof, in native form or pharmaceutically acceptable salts thereof.
• Pharmaceutical formulations for using the compounds according to the invention may be prepared using conventional techniques. The formulations include those suitable for oral use, for instance capsules, tablets, suspensions, emulsions, solutions; sterile solutions for parenteral use (including subcutaneous, intramuscular and intravenous administration), or preparations for topical or rectal use or other forms suitable for obtaining the desired therapeutic effect, for example solid formulations for oral use with delayed action, which allow a slow release of the active principle over time. Substances commonly used in the pharmaceutical field as excipients, binders, disintegrants and substances capable of stimulating transdermal absorption may be used together with the active principle in the pharmaceutical formulation.
• Neboglamine compounds, such as the racemic mixture thereof, may thus be used in native form or as pharmaceutically acceptable salts. In the case of neboglamine, it is preferably the sodium or potassium salt or the hydrochloride.
• The effective therapeutic amount of neboglamine to be used for the treatment of drug-induced toxicodependency should be between 10 and 600 mg and preferably from 30 to 300 mg per day of active principle, depending on the specific conditions of the treated patient, and the individual response to the treatment, the age and the weight of the patient.

Claims (12)

1. Use of neboglamine, (S)-4-amino-N(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs.

2. Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the therapeutic treatment of drug-induced abstinence crises.

3. Use of neboglamine, the racemic mixture thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapeutic treatment of drug-induced tolerance phenomena.

4. Use according to any of claim 1, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of the active substances.

5. The use according to claim 1, wherein neboglamine is administered in a therapeutically effective amount of from 10 to 600 mg/day.

6. The use according to claim 1, wherein neboglamine is administered in a therapeutically effective amount of from 30 to 300 mg/day.

7. The use according to claim 1, wherein said drug is a CNS sedative, a stimulant or a hallucinogen.

8. The use according to claim 7, wherein said CNS sedative is selected from opiates, barbiturates, benzodiazepines and alcohol.

9. The use according to claim 7, wherein said stimulants are selected from amphetamines and cocaine.

10. The use according to claim 7, wherein said hallucinogens are selected from LSD, mescaline, cannabis (marijuana) or phencyclidine.

11. Use according to claim 2, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances.

12. Use according to claim 3, wherein said medicament also comprises pharmaceutically acceptable inactive ingredients, selected from the group consisting of vehicles, binders, flavourings, sweeteners, disintegrants, preserving agents and humectants and mixtures thereof, or ingredients that facilitate the oral, parenteral, transdermal, transmucosal or rectal adsorption and that allow time-controlled release of active substances.